Corteria Pharmaceuticals

#Cardiometabolic diseases #Clinical trials #Corteria Pharmaceuticals #Heart failure #Obesity

Corteria Pharmaceuticals initiates two trials with its CRF2 agonists

Corteria Pharmaceuticals has initiated a Phase II trial in heart failure and Phase I trial in obesity with its first-in-class corticotropin‑releasing factor receptor 2 (CRF2) agonists, COR‑1167 and COR‑1389.  CRAFT-WHF Phase II trial of COR-1167 in worsening heart failure COR-1167… Read More

#News

Heart
#Clinical trials #Corteria Pharmaceuticals #Heart failure #Hormone therapy #Worsening Heart Failure

Phase I study to evaluate treatment of worsening heart failure 

Corteria Pharmaceuticals has initiated a Phase I study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure (WHF).  COR-1167 is a once-daily subcutaneous CRF2 agonist that has demonstrated substantial protective effects and functional improvement in the heart,… Read More

#News